Asset
OLUTASIDENIB
Rigel Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07486713 | phase4 | recruiting | 2026-02-23 | 2027-04-30 | Rigel Pharmaceuticals | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies |
| NCT06161974 | phase2 | recruiting | 2025-02-01 | 2029-06-01 | Rigel Pharmaceuticals | Study of Olutasidenib and Temozolomide in HGG |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 215814 | NDA | RIGEL PHARMACEUTICALS INC |
Marketed products (1)
- REZLIDHIA